Is Biogen’s Aducanumab Approvable? Opinions Divided Ahead Of Review
FDA Committee Meets On 6 November
Executive Summary
Many clinicians doubt that aducanumab can really help slow the decline in Alzheimer’s patients – but US FDA could offer it the benefit of the doubt.
You may also be interested in...
Biogen's Aducanumab Advisory Committee Will Test US FDA's 'Substantial Evidence' Flexibility
Given inconsistent study results, robustness of the efficacy evidence is expected to be key focus of the 6 November meeting of the Peripheral and Central Nervous System Drugs Advisory Committee; review could put a December 2019 guidance on the ‘substantial evidence’ standard to the test and offer insight into the amount of flexibility the agency is willing to exercise for neurodegenerative diseases with high unmet need.
Biogen's US Tecfidera Sales Could Plunge By $2.8bn In 2021
Mylan’s “at-risk” launch of a generic version of Biogen’s Tecfidera could cost the originator dear as generic competition to the one of the most lucrative small-molecule opportunities arrives in the US.
Novartis Nominates Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.